Moreover, data confirm that PCSK9 inhibition using alirocumab or evolocumab potentiates immune checkpoint inhibition therapy, specifically anti-PD1 antibody treatment, in mouse models of cancers [159]. The gene discussed is PCSK9; the disease is cancer.